Krystal Biotech, Inc.
KRYS
株式のランク
#2124
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
株価
$326.41
最終同期: 2026-10-20
時価総額
$9.66B
変化（1日）
1.92%
変化（1年）
71.09%
国
US
取引 Krystal Biotech, Inc. (KRYS)
カテゴリー
Healthcare
Krystal Biotech, Inc.（KRYS）の収益
Jun 2026 時点の収益 TTM: $440.48M
Krystal Biotech, Inc. の最新の財務報告によると、現在の収益 (TTM) は $440.48M です。2023 年には $50.70M の収益があり、これは 2022 年の 0.00 と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Krystal Biotech, Inc. の収益履歴（2016 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $440.48M | 51.62% |
| 2024 | $290.52M | 473.02% |
| 2023 | $50.70M | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | -100.00% |
| 2018 | $1.03M | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 2,766.01% |
US
|
|
| $2.23B | 405.81% |
US
|
|
| $15.74B | 3,474.32% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 1,266.97% |
NL
|
